SCHEMBL3169303

SCHEMBL3169303

CC(C)C[C@H](NC(=O)[C@@H](NS(=O)(=O)c1ccc2ccccc2c1)[C@@H](C)O)B(O)O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.55
LARS1 Q9P2J5 1/20 0.54
PSMB5 P28074 15/20 0.48
PSMB1 P20618 2/20 0.48
PSMB2 P49721 2/20 0.48
PSMB8 P28062 2/20 0.48
ELANE P08246 1/20 0.48
CTSG P08311 1/20 0.48
CYP3A4 P08684 1/20 0.48
CMA1 P23946 1/20 0.48
PSMB9 P28065 1/20 0.48
PSMB10 P40306 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48
CAPN1 P07384 2/20 0.44
CTSB P07858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025842 0.81 ADAM17 (0.60) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL4925808 0.81 ADAM17 (0.60) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL3170541 0.79 PSMB5 (0.59) ADAM17PSMB5PSMB1PSMB2PSMB8
SCHEMBL609430 0.79 SLC1A3 (0.51) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL15291200 0.79 PSMB5 (0.46) ADAM17LARS1PSMB5PSMB1PSMB2
SCHEMBL609429 0.78 LARS1 (0.50) ADAM17LARS1CYP3A4SLC1A3SLC1A2
SCHEMBL27486757 0.77 ADAM17 (0.55) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL6984103 0.77 ADAM17 (0.55) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL3915375 0.77 CAPN1 (0.64) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL12754551 0.75 PSMB5 (0.44) ADAM17LARS1PSMB5PSMB1PSMB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-8058262-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-11-15 US disclosed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 ADAM17 1842/4885LARS1 1449/4885PSMB5 2/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 ADAM17 1842/4885LARS1 1449/4885PSMB5 2/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 ADAM17 1842/4885LARS1 1449/4885PSMB5 2/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 ADAM17 1842/4885LARS1 1449/4885PSMB5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.